European Medicines Agency validates type II variation application for Padcev (enfortumab vedotin) with Keytruda (pembrolizumab) for first-line treatment of advanced bladder cancer.- Astellas + Pfizer
Astellas Pharma Inc. and Pfizer Inc. announced that on January 26 , 2024 the European Medicines Agency (EMA) validated for review a Type II variation application for Padcev (enfortumab vedotin) with Keytruda (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
If approved, Padcev with Keytruda has the potential to change the treatment paradigm, becoming the first combination treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC.
Globally, approximately 573,000 new cases of bladder cancer and 212,000 deaths are reported annually. It is estimated that approximately 200,000 people in Europe are diagnosed with bladder cancer each year.
Roger Dansey, M.D., Chief Development Officer, Oncology, Pfizer; "The EV-302 pivotal trial demonstrated the benefits of combining PADCEV with pembrolizumab for advanced bladder cancer. Patients with bladder cancer in Europe face poor outcomes at the advanced stage, and innovative therapies that extend survival are needed. This acceptance brings us closer to our mission: delivering breakthroughs that help address the unmet needs of patients and reshape the advanced urothelial cancer treatment landscape."
The FDA approved the combination therapy in December 2023..
Related news and insights
RAPT Therapeutics, Inc. announced that the FDA has verbally notified the company that a clinical hold has been placed on the company’s Phase IIb trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase IIa trial in asthma
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental new drug application (sNDA) for Krazati (adagrasib) in combination with cetuximab for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC)
Tenax Therapeutics, Inc., a Phase III, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)